injectable glp-1 agonists How medications are transforming diabetes and weight loss treatment List of approved and pending
Description
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
David Kessler says the new weight-loss drugs are a powerful tool to fight obesity
Incorporating this botanical product into a balanced diet supports healthy metabolism as well as regular digestive and muscle function without risking undernutrition.*
GLP-1 receptor agonists are medications used to manage obesity and type 2 diabetes
The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health care spending.
